{"filings":[{"id":1664717,"accession_number":"0001493152-26-033360","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-07-15T20:15:43+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Millard resigned as Chief Operating Officer on July 10, 2026.","Resignation notice received and effective on the same date.","No replacement or interim COO has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-15","daily_digest_url":"/daily/2026-07-15","daily_digest_rank":1},{"id":611316,"accession_number":"0001493152-26-025061","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-05-22T20:55:24+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Ensysce of delisting risk for equity shortfall","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.","Must submit a plan by July 6, 2026 (45 days) to regain compliance; if accepted, extension up to 180 days from May 21.","Company plans to submit a timely plan and explore options, but no assurance Nasdaq will accept or extension granted.","Failure could lead to delisting; company may appeal to Nasdaq Hearings Panel if plan rejected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":471360,"accession_number":"0001493152-26-023810","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-05-15T20:20:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Q1 net loss $3.6M; cash $0.7M; Phase 3 trial 50% enrolled; strategic review underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders $3.6M vs $1.9M in Q1 2025; R&D expense rose to $3.3M on Phase 3 costs.","Cash and equivalents $0.7M at March 31, 2026; subsequent $2.0M convertible preferred financing closed April 7.","Achieved 50% of interim enrollment target in pivotal PF614-301 Phase 3 trial for moderate to severe pain.","IRB approval secured for Part 3 of PF614-MPAR-102; first peer-reviewed MPAR data published in Journal of Opioid Management.","Board initiated formal review of strategic alternatives, including partnerships and licensing opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":960999.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94943,"accession_number":"0001493152-26-015602","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ensysce closes $2M preferred stock financing from prior $20M commitment; conversion price $0.55","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2M from second tranche under November 2025 agreement; net ~$1.9M for TAAP and MPAR programs and working capital.","Conversion price fixed at $0.55 per share; warrants with 100% coverage (18-month and 5-year terms) at $0.55 exercise price.","Amended Series B preferred stated value from $1,100 to $1,200 per share and issued 8,727,273 warrants.","CEO Lynn Kirkpatrick states financing reflects continued investor confidence in the company's analgesic programs.","Financing is part of up to $20M commitment available over 24 months from institutional investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94942,"accession_number":"0001493152-26-015139","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Curtis Rosebraugh resigns from Ensysce Biosciences board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation effective April 1, 2026; no reason given in notice.","Rosebraugh served on the Nominating and Corporate Governance Committee until resignation.","Resignation notice filed as Exhibit 17 to the 8-K.","No replacement announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107684,"accession_number":"0001493152-26-013622","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Biosciences reports Q4 2025 net loss of $2.8M, advances PF614 Phase 3 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $4.3M at Dec 31, 2025; net loss for 2025 $10.2M vs $8.0M in 2024.","R&D expenses rose $3.2M to $10.4M due to clinical programs for PF614 and PF614-MPAR.","Enrolled first patient in Phase 3 trial (PF614-301) for moderate-to-severe post-surgical pain.","FDA supports streamlined 505(b)(2) pathway for PF614-MPAR with overdose-protection labeling.","USPTO allowed new MPAR patent covering composition-of-matter and method-of-use claims through 2042."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107683,"accession_number":"0001493152-26-013314","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Lee Rauch resigns from Ensysce board over severance package dispute","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lee Rauch resigned effective March 24, 2026, citing disagreement with board-approved severance packages.","Packages provide up to $205,475 in potential severance for CFO and three managers during strategic review.","CFO retention package increased from 6 to 9 months; packages contingent on non-retention in any strategic deal.","Board approved packages on March 27, 2026; Rauch had previously expressed other disagreements.","Company continues evaluating strategic alternatives for its business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107682,"accession_number":"0001493152-26-012062","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ensysce corrects scrivener's error in Series B Preferred Stock designation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed Certificate of Correction on March 18, 2026 to fix a scrivener's error in the Series B Preferred Stock designation.","Correction is to the Certificate of Designation, which is part of the Certificate of Incorporation.","No change in the rights or terms of the Series B Preferred Stock as a result of the correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107681,"accession_number":"0001493152-26-008343","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ensysce Biosciences receives Nasdaq deficiency notice for bid price below $1","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Feb 25, 2026; bid price closed below $1 for 30 consecutive business days.","Company has 180 days, until August 24, 2026, to regain compliance by closing at $1 for 10 consecutive days.","If not compliant by Aug 24, Nasdaq may grant a second 180-day period if other listing standards met.","Company intends to monitor bid price and evaluate options; trading on Nasdaq continues under ENSC.","Failure to regain compliance could lead to delisting, impairing capital raising and market liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107680,"accession_number":"0001493152-26-000994","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ensysce shareholders approve share issuance to investor and incentive plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issuance of common stock and warrants to an investor approved: 541,882 for, 195,475 against, 1,030,540 broker non-votes.","Amendment to 2021 Omnibus Incentive Plan approved, increasing authorized shares from 121,457 to 721,457.","Class I directors William Chang and Lee Rauch reelected; Chang: 518,597 for, Rauch: 516,907 for.","Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124051,"accession_number":"0001493152-25-023933","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Ensysce Biosciences closes $4M convertible preferred stock financing with up to $20M available","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed $4M convertible preferred stock financing; up to $16M additional available in future tranches over 24 months.","Conversion price fixed at $2.50/share; 50% warrant coverage exercisable at same price for five years.","Proceeds to accelerate Phase 3 clinical development of PF614, a novel abuse-resistant analgesic.","Series B preferred pays 4% annual dividend (8% on triggering events); stated value $1,100 per share.","Net proceeds from the offerings estimated at ~$3.6 million for general corporate purposes and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124050,"accession_number":"0001493152-25-023492","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Q3 net loss $3.7M; Phase 3 PF614 trial started; FDA backs PF614-MPAR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders was $3.7M for Q3 2025, vs. a gain of $0.7M in Q3 2024.","Cash totaled $1.7M as of Sept 30, 2025; completed convertible preferred stock offering in Nov 2025 for $4M gross, with up to $16M additional over 24 months.","Initiated pivotal Phase 3 trial (PF614-301) for PF614 in moderate to severe post-surgical pain in July 2025.","FDA supported PF614-MPAR development for overdose protection labeling and confirmed potential streamlined 505(b)(2) pathway.","R&D expenses increased to $3.0M from $1.7M YoY; grant revenue fell to $0.5M from $3.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":3184314.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140727,"accession_number":"0001641172-25-023500","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Biosciences reports Q2 2025 net loss of $1.7M, advances Phase 3 trial for PF614","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $2.2M at June 30, 2025, down from $3.5M at Dec 31, 2024.","Net loss $1.7M in Q2 2025 vs $2.0M loss in Q2 2024; R&D expenses rose to $1.9M from $0.9M.","Federal grant revenue $1.4M in Q2 2025 vs $0.2M in Q2 2024, driven by MPAR study activity.","Initiated pivotal Phase 3 trial (PF614-301) for post-surgical pain; Rho, Inc. engaged as CRO.","Received $5.3M NIDA installment and U.S. patent allowance for OUD candidate PF9001."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2691210.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158466,"accession_number":"0001641172-25-013853","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ensysce Biosciences auditor changes to Baker Tilly after Moss Adams merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Moss Adams merged into Baker Tilly effective June 3, 2025; Baker Tilly appointed as successor auditor.","No disagreements or reportable events with Moss Adams during fiscal years 2024 and 2023.","Moss Adams' prior audit reports included a going concern explanatory paragraph.","Company had no consultations with Baker Tilly before appointment.","Moss Adams provided a letter agreeing with the statements in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158465,"accession_number":"0001641172-25-009949","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Q1 net loss narrows to $1.9M; PF614-MPAR trial Part 1 completes, patent allowed for OUD candidate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.9M vs $3.1M in Q1 2024; R&D spend rose to $1.9M on PF614-MPAR activity.","Cash $3.1M at March 31, 2025; subsequent warrant exercises raised $2.2M gross.","PF614-MPAR-102 Part 1 confirmed overdose protection at higher doses; Parts 2 & 3 enrollment underway.","U.S. patent allowed for PF9001 (OUD) covering composition of matter and method of use.","Federal grant funding increased to $1.3M from $0.3M, supporting MPAR and OUD programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":1319772.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158464,"accession_number":"0001641172-25-006009","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ensysce raises $2.2M via warrant exercise inducement; issues new warrants for 1.26M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercised 630,376 warrants at $3.24/share for cash; gross proceeds ~$2.2M before fees.","Company issued new unregistered warrants to purchase 1,260,752 shares at $1.90, split 18-month and 5-year terms.","Net proceeds ~$1.9M to fund TAAP and MPAR programs and working capital.","H.C. Wainwright acted as placement agent; received 7% cash fee and 44,126 agent warrants at $4.05.","New warrants include 4.99% beneficial ownership limitation (9.99% at holder election)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158463,"accession_number":"0001641172-25-002087","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ensysce corrects auditor consent to include omitted S-3 registration statements","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Original consent filed March 10, 2025 with Form 10-K omitted references to Registration Statements No. 333-275456 and No. 333-276537.","Revised consent dated April 1, 2025 is filed as Exhibit 23.1 to this 8-K.","No change to any previously reported financial results or disclosures in the 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176837,"accession_number":"0001641172-25-001751","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ensysce Biosciences closes $1.1M registered direct offering and private placement of warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $1.1M from sale of 315,188 shares (or equivalents) at $3.49/share.","Concurrent private placement: Series A-5 warrants (18-month term) and Series A-6 warrants (5-year term), each exercisable at $3.24/share.","Net proceeds of ~$0.9M to fund TAAP and MPAR program development and working capital.","H.C. Wainwright acted as exclusive placement agent; placement agent warrants for 22,063 shares at $4.3625/share.","30-day lock-up on further equity issuance and insider sales; beneficial ownership limitation of 4.99% (or 9.99%) on warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176836,"accession_number":"0001493152-25-009695","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.","Entered strategic partnership with specialty manufacturer for commercial launch of PF614 and PF614-MPAR.","PF614-MPAR-102 interim data show overdose protection at 100 mg dose; study continues at higher doses.","FDA feedback on PF614 phase 3 design received; enrollment expected Q2 2025; NDA submission targeted for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176835,"accession_number":"0001493152-25-004880","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ensysce secures up to $10M R&D funding from Galephar in equity-based development deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Galephar commits up to $10 million to support R&D, manufacturing, and testing of PF614 and PF614-MPAR.","Ensysce issues 1% of outstanding shares as restricted stock vesting in thirds based on project milestones.","Development costs compensated with 50% restricted stock and 50% freely tradeable shares at 1.2x actual cost.","15-year term with IP created related to Ensysce's products owned exclusively by Ensysce.","Share price fixed using trailing five-day closing price; no future variable pricing permitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193641,"accession_number":"0001493152-24-048497","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ensysce Biosciences announces 1-for-15 reverse stock split effective Dec 6, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-15 ratio, effective 12:01 am on December 6, 2024.","Stockholders approved range of 1:10 to 1:40; board selected 1:15 ratio.","No fractional shares issued; fractional shares rounded up to nearest whole share.","Proportionate adjustments to warrants, stock options, and RSUs will be made.","New CUSIP number for post-split common stock is 293602504."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193640,"accession_number":"0001493152-24-047149","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ensysce stockholders approve reverse stock split authorization and director elections at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved issuance of shares/warrants to investors: 3,102,053 for, 210,141 against (3,995,063 broker non-votes).","Authorized reverse stock split with ratio range 1-for-10 to 1-for-40; board sets exact ratio: 4,561,369 for, 1,989,571 against.","Elected Class III directors Dr. Lynn Kirkpatrick, Dr. Adam Levin, and Mr. Steve Martin (each >2M votes for).","Ratified Moss Adams LLP as auditor for FY 2024: 5,978,860 for, 259,207 against, 1,250,026 abstentions.","Fifth proposal to adjourn meeting if needed was not voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193639,"accession_number":"0001493152-24-044760","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce reports Q3 net income of $0.7M; awarded $14M NIH grant for PF614-MPAR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $0.7M vs net loss of $2.7M in Q3 2023; driven by $3.4M in federal grant revenue.","Cash & equivalents $4.2M at Sept 30, 2024, up from $1.1M at Dec 31, 2023; $8.5M raised in equity financings.","Awarded $14M multi-year NIH grant for PF614-MPAR; second Phase 1b trial initiated.","Pivotal PF614 Phase 3 protocol submitted to FDA; feedback expected by end of November.","Stockholders' equity $6.6M, compliant with Nasdaq $2.5M listing requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":3906372.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193638,"accession_number":"0001493152-24-041589","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ensysce Biosciences reduces stockholder quorum to 1/3 of votes, effective Nov 1, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bylaw amendment lowers quorum from majority to 1/3 of total votes entitled to be cast.","Change approved by board on October 17, 2024; effective November 1, 2024.","No other amendments or fiscal year changes were reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209960,"accession_number":"0001493152-24-034451","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ensysce Biosciences raises $5M in concurrent registered direct offering and warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5M from sale of 3.55M shares (or equivalents) at $0.47 per share and exercise of 7.2M outstanding warrants at reduced price.","Concurrent private placement of unregistered Series A-3 and A-4 warrants to purchase up to 28.7M shares, exercisable after stockholder approval.","Net proceeds to fund TAAP and MPAR programs and supplement recently announced $14M NIH grant for PF614-MPAR.","Existing warrants from November 2023 amended to $0.47 exercise price effective upon closing; stockholder approval required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209959,"accession_number":"0001493152-24-033731","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ensysce Biosciences receives Nasdaq delisting notice for equity shortfall","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received August 20, 2024; non-compliance with $2.5 million stockholders' equity minimum as of June 30, 2024.","Company plans to timely request a hearing before the Nasdaq Hearings Panel, which will stay delisting action.","No assurance that the Panel will grant continued listing or that compliance can be shown before any extension expires."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209958,"accession_number":"0001493152-24-032272","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Biosciences Q2 2024 net loss $2.0M; PF614-MPAR Phase 1b and OUD candidate PF9001 advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders was $2.0M in Q2 2024 vs $2.2M in Q2 2023.","Cash and cash equivalents totaled $1.0M at June 30, 2024, down from $1.1M at year-end 2023.","R&D expense fell to $0.9M from $1.6M YoY, driven by lower clinical and pre-clinical costs.","PF614-MPAR Phase 1b study (PF614-MPAR-102) progressing with Quotient Sciences; overdose protection verification planned.","PF9001 selected as lead OUD candidate in June; supported by NIH/NIDA HEAL award up to $15M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":487519.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228148,"accession_number":"0001493152-24-021456","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ensysce regains Nasdaq compliance with equity requirement, common stock continues trading","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice on May 24, 2024 from Nasdaq of regained compliance with Listing Rule 5550(b)(1) equity requirement.","Common stock will continue trading on Nasdaq Capital Market tier; delisting risk removed for now.","Company must maintain all Nasdaq listing requirements going forward; no assurance of future compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228147,"accession_number":"0001493152-24-018793","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Biosciences reports Q1 net loss of $3.1M; advances PF614 Phase 3 plans","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders was $3.1M for Q1 2024, vs $2.2M in Q1 2023.","Cash increased to $3.4M at March 31, 2024 from $1.1M at Dec 31, 2023, boosted by $6.8M in warrant exercises.","R&D expenses decreased to $0.8M from $1.8M YoY; G&A decreased to $1.4M from $1.6M.","FDA granted Breakthrough Therapy designation for PF614-MPAR in January; Phase 3 trial for PF614 expected to start H2 2024.","Federal grant revenue fell to $0.3M from $0.8M due to completion of MPAR grant in Dec 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":305722.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228146,"accession_number":"0001493152-24-018482","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ensysce Biosciences believes it regains Nasdaq stockholders' equity compliance after warrant exercise","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company believes it now has at least $2.5M stockholders' equity, satisfying Nasdaq listing rule.","February 2024 warrant exercise generated gross proceeds of ~$4.7M.","Previously received Nasdaq extension to May 13, 2024 to evidence compliance.","Awaiting Nasdaq formal confirmation of compliance status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246912,"accession_number":"0001493152-24-011871","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ensysce Biosciences receives Nasdaq deficiency notice for bid price below $1.00, given 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on March 27, 2024 for bid price closing below $1.00 for 30 consecutive business days.","Has until September 23, 2024 to regain compliance by maintaining $1.00 bid price for at least 10 consecutive business days.","Also has prior stockholders' equity non-compliance; Nasdaq Panel granted continued listing until May 13, 2024.","Company will monitor closing bid price and evaluate options, but no assurance of regaining or maintaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246911,"accession_number":"0001493152-24-010014","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce reports FY2023 net loss of $10.6M; cash $1.1M; FDA Breakthrough for PF614-MPAR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $3.5M vs $5.5M; full year $10.6M vs $25.1M (prior year).","Cash $1.1M at Dec 31, 2023; raised $6.8M from warrant exercises in Jan & Feb 2024.","R&D expenses fell to $2.2M (Q4) and $7.6M (FY) from $6.4M and $19.8M.","FDA granted Breakthrough Therapy designation for PF614-MPAR in January 2024.","Phase 3 enrollment for PF614 expected H2 2024 after positive End-of-Phase 2 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246910,"accession_number":"0001493152-24-006773","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ensysce raises $4.7M via warrant exercise, issues new warrants at $1.06","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.7M from cash exercise of 3,601,752 existing warrants at reduced price $1.31 per share.","Issues unregistered Series A/B warrants for 7,203,504 shares at $1.06; Series A expire 18 months, Series B May 2028.","Net proceeds for Phase 3 prep of PF614, debt repayment (Oct/Nov 2023), and general corporate.","Placement agent H.C. Wainwright gets $200k fee and 252,123 warrants at $1.6375.","Waiver from Oct 2023 SPA requires full note repayment with premium post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264349,"accession_number":"0001493152-23-046578","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["8.01","5.07"],"status":"ready","headline":"Ensysce Biosciences special meeting canceled again due to lack of quorum; no vote on matters","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting of stockholders scheduled for December 29, 2023 was not held due to lack of quorum.","No matters were submitted to a vote; company had sought approval for matters related to October 23 Securities Purchase Agreement.","Company must call a meeting every four months until stockholder approval is obtained or notes issued under Agreement are no longer outstanding.","This is the second postponement; the meeting was originally set for December 20, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264348,"accession_number":"0001493152-23-045413","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ensysce Biosciences postpones special meeting to Dec 29 due to quorum shortfall","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special Meeting postponed from Dec 20 to Dec 29, 2023 at 9:00 a.m. PT.","Lack of required quorum (one third of outstanding common stock) prompted delay.","Record date Oct 30, 2023 unchanged; proposals and meeting link remain the same.","Company continues soliciting votes; further postponement possible if quorum still lacking, incurring extra costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264347,"accession_number":"0001493152-23-043009","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Ensysce completes $1.7M convertible note financing; second closing of $1.133M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total gross proceeds of $1.7M from senior secured convertible notes and warrants; second closing on Nov 28/29, 2023 added $1.133M (net).","Notes convertible at $1.5675/share, 6% interest, 6-month term; monthly redemption begins 90 days after issuance.","Warrants to purchase up to 3.77M shares at $1.5675, exercisable for five years from issuance.","Proceeds to fund PF614 time of onset study and regulatory milestones.","Notes secured by all company assets and guaranteed by subsidiaries EBI OpCo and EBI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264346,"accession_number":"0001493152-23-041881","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ensysce Biosciences receives Nasdaq delisting notice for non-compliance with $2.5M equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notified on Nov 13, 2023 of non-compliance with Nasdaq Rule 5550(b)(1) due to stockholders' equity below $2.5M as of Sept 30, 2023.","Company plans to timely request a hearing before Nasdaq Hearings Panel, staying delisting pending hearing conclusion.","No assurance the Panel will grant continued listing or that compliance can be evidenced within any extension period.","Company intends to actively explore options to regain compliance with Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264345,"accession_number":"0001493152-23-040100","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Q3 net loss narrows to $2.7M; cash $1.5M; PF614 study results expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders was $2.7M ($0.87/share) vs $9.9M ($61.58) in Q3 2022.","Cash and cash equivalents $1.5M as of Sep 30, 2023, down from $3.8M at June 30; post-quarter raised $1.7M in convertible notes.","R&D expenses fell to $1.9M from $4.8M; G&A expenses fell to $1.2M from $1.7M.","PF614-201 time-of-onset study results expected in December 2023; FDA End of Phase 2 meeting set for Jan 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1715488.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264344,"accession_number":"0001493152-23-038049","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Ensysce Biosciences raises $1.7M in convertible note and warrant private placement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate investment of $1.7M through senior secured convertible notes and warrants; initial close of $566,667 on or before Oct 26.","Notes convertible at $1.5675 per share, bear 6% interest, 6-month maturity, 8% original issue discount.","Warrants to purchase up to 1,255,697 shares at $1.5675 exercisable for 5 years; second close of $1,133,333 upon SEC registration effectiveness.","Proceeds to fund clinical development of TAAP and MPAR platforms, including time-of-onset study for PF614.","Obligation to begin monthly principal and interest payments in cash or stock at holder's election after 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281590,"accession_number":"0001493152-23-030391","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ensysce shareholders elect directors, approve share increase, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class II directors Bob Gower and Curtis Rosebraugh elected with 222,281 and 223,255 votes for, respectively.","Amendment to 2021 Omnibus Incentive Plan approved, increasing authorized shares from 31,296 to 617,092 (202,246 for, 50,153 against).","Ratification of Moss Adams LLP as independent auditor for FY 2023 approved with 1,631,139 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281589,"accession_number":"0001493152-23-027730","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Biosciences Q2 net loss $2.2M; cash $3.8M; IRB approves key PF614 study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2023 was $2.2 million versus $7.9 million in Q2 2022; EPS ($0.98) vs ($56.49).","Cash and cash equivalents $3.8 million at June 30, 2023, up from $1.4 million at March 31; increase driven by May 2023 public offering with $7.0 million gross proceeds.","R&D expenses decreased to $1.6 million in Q2 2023 from $5.3 million in Q2 2022 due to timing of clinical studies.","IRB approval received for PF614-201 protocol, a key Phase 3 study; End of Phase 2 meeting with FDA anticipated later this year.","Positive results from oral abuse potential study (PF614-104) and overdose protection Phase 1 study (PF614-MPAR-101) completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":1280107.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300461,"accession_number":"0001493152-23-021113","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ensysce Biosciences regains compliance with Nasdaq equity requirement on June 13","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received formal notice from Nasdaq that it now meets the equity requirement under Listing Rule 5550(b)(1).","The Nasdaq Hearings Panel matter concerning listing compliance has been closed.","Ensysce common stock (ENSC) will continue trading on the Nasdaq Capital Market.","Company cautioned that future compliance with all Nasdaq requirements is not guaranteed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300460,"accession_number":"0001493152-23-019987","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ensysce completes $7M offering, believes it meets Nasdaq equity requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$7M gross via public offering of common stock and warrants on May 12, 2023.","Previously notified of non-compliance with Nasdaq's $2.5M stockholders' equity minimum.","Hearings Panel granted extension to June 12, 2023; company now believes it satisfies the Rule.","Awaiting formal Nasdaq confirmation of compliance status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300459,"accession_number":"0001493152-23-017038","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ensysce closes $7M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 1,800,876 shares (or pre-funded warrants) plus Series A-1/A-2 warrants at $3.887 per unit.","Gross proceeds ~$7M; net proceeds for clinical development and working capital.","H.C. Wainwright acted as exclusive placement agent for the offering.","Amended 210,085 existing warrants from $16.80-$187.20 to $3.637 per share at $0.125 per amended warrant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300458,"accession_number":"0001493152-23-011751","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ensysce Biosciences dismisses Mayer Hoffman McCann, appoints Moss Adams as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Moss Adams LLP as independent registered public accounting firm effective April 10, 2023.","Dismissed former auditor Mayer Hoffman McCann P.C. (MHM) effective the same date.","No disagreements or reportable events with MHM during 2021-2022 or interim period.","MHM's audit reports included explanatory paragraph about substantial doubt on company's going concern.","MHM letter filed as Exhibit 16 concurring with company's disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320472,"accession_number":"0001493152-23-009856","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce reports FY2022 net loss $24.2M, cash $3.1M; $3M equity raise; clinical milestones achieved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $5.5M ($10.0M prior year); FY2022 net loss $24.2M ($29.1M prior year).","Cash at Dec 31, 2022 $3.1M, down from $12.3M year ago; raised $3M post-year-end at $0.84/share.","R&D expenses Q4 $6.4M (up from $2.2M prior year); FY $19.8M (up from $4.7M prior year) due to clinical trials.","Clinical progress: PF614 oral HAP study database locked Feb 2023; FDA guidance supports acute pain indication; PF614-MPAR Phase 1 fully enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":789635.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320471,"accession_number":"0001493152-23-009637","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ensysce Biosciences effects 1-for-12 reverse stock split effective March 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-12 ratio, effective 12:01 am on March 31, 2023.","New CUSIP number 293602405; no fractional shares issued, cash paid in lieu.","Exercise prices and shares of warrants, options, and RSUs adjusted proportionately.","Series A Preferred Stock redeemed in connection with the reverse split.","Stockholders approved the split on March 23, 2023; board set ratio at 1-for-12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320470,"accession_number":"0001493152-23-008904","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Ensysce shareholders approve reverse stock split at ratio of 1:5 to 1:12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split proposal approved with 2,836,326,468 For, 280,656,829 Against, 19,762,315 Abstain.","Board authorized to set exact ratio between 1-for-5 and 1-for-12 at its discretion.","Second proposal lacked quorum and was not voted; adjournment proposal not submitted.","Special meeting held March 23, 2023; only reverse split proposal was submitted to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320469,"accession_number":"0001493152-23-003873","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Ensysce Biosciences closes $3.0M registered direct offering of 3.57M shares at $0.84/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3.0M from sale of 3,571,431 common shares at $0.84 per share in registered direct offering.","Concurrent private placement: warrants to purchase up to 3,571,431 shares at $0.715, exercisable for 5.5 years.","Board increased authorized Series A Preferred shares to pay stock dividend of 0.001 share per common share; record date Feb 13, 2023.","H.C. Wainwright acted as placement agent; received 7% cash fee and warrants to buy 250,000 shares at $1.05.","Company has 30-day lockup; officers and directors have 90-day lockup on further equity sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320468,"accession_number":"0001493152-23-003270","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Ensysce declares Series A Preferred dividend with 1,000 votes per 0.001 share, tied to reverse split vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declares dividend of 0.001 Series A Preferred share per common share; record date Feb 13, 2023.","Each 0.001 of a share carries 1,000 votes; voting limited exclusively to reverse split and adjournment proposals.","Preferred shares are non-transferable except with common; automatically redeemed if not voted at the meeting.","Liquidation preference of $0.0001 per share; no dividend or conversion rights; filing of Certificate of Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4408347.317073171,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-01T23:59:59+00:00|320468"}